KBR and HJF bags contract to aid military neuroscience research

KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE

WHO issues warning on the surge of new age gateway devices among children

Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use

Pfizer presents marstacimab Phase 3 Data at ASH 2023

Demonstrate significant bleed reduction in hemophilia A and B

ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346

First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone

Pradeep Chakravarty joins Alembic Pharmaceuticals as Head - Global Quality

Prior to joining Alembic, he was working with Lupin Limited for more than 11 years

AstraZeneca Pharma appoints Venkat Natarajan as Lead - Market Access

Currently, Venkat is Lead – Market Access, India at Pfizer

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels